mesenchymal stem cell

(redirected from Mesenchymal stem cells)

mesenchymal stem cell

A pluripotent cell that differentiates into connective tissue cells.

mesenchymal stem cell

A stem cell found in connective tissue and capable of producing cells of the connective tissue lineages, such as cartilage, bone, muscle, and fat cells.
See also: cell
References in periodicals archive ?
It took three years for the team to achieve the findings, which showed human mesenchymal stem cells are capable of preventing inflammation in the lungs of mice and then reverse the progression of the disease by enacting macrophages to eat up the scars on the tissue, thus repairing lung cells and turning the hard fibrosis into soft tissue, the team said.
Using engineered mesenchymal stem cells as the "bio-factory" to mass-produce miR-185, which functionally serves to suppress cancer cell proliferation, invasion and migration, in the cell culture system, the resulting miR-185 enriched exosomes were isolated and externally applied to the oral leukoplakia lesions in animal models as a proof-of-concept study.
In addition, the company is developing a next-generation platform using cultured mesenchymal stem cells to protect and potentiate the virus, a highly scalable off-the-shelf, allogeneic cell-based delivery technology.
But the scientists say that mesenchymal stem cells aren't the best sources for extracellular vesicles.
Although the origin of the disease remains unclear, the most likely candidates are seen as mesenchymal stem cells (MSCs) or osteoprogenitor cells (3).
In the craniofacial region, bone marrow mesenchymal stem cells (BMMSC), dental pulp stem cells (DPSCs), periodontal ligament stem cells (PDLSCs), and stem cells from human exfoliated deciduous (SHED) teeth have been identified as potential ones, which have regenerative capacity.
Zhong Ensheng Medical, a regenerative medicine company that promotes allogeneic mesenchymal stem cells, was established in 2009 to develop new drags from adipose mesenchymal stem cells.
FDA approved the company's second-Phase clinical implementation of a new drug using allogeneic mesenchymal stem cells.
Bone marrow mesenchymal stem cells (BMSCs), a type of adult stem cells with self-replicating and multidirectional differentiation potential from bone marrow, are characterized by strong proliferation, low immunogenicity, differentiation to osteoblasts, and migration to the lesion after transplantation.
In human skin five different niches have been identified in basal layer of the epidermis, bulge region of the hair follicle, in the dermis, in dermal papillae and in the base of sebaceous glands.1 Mesenchymal stem cells (MSCs) are stem cells that are multipotent and can differentiate into different cell types.
Japan-based California, US-based pharmaceutical corporation The SanBio Group, a developer of regenerative medicine for neurological disorders, has acquired a patent portfolio regarding cell medicines derived from Mesenchymal Stem Cells, the company said.
Mesenchymal stem cells (MSCs) are one of major cellular constituents in intestinal tumor, which contribute to carcinogenesis via interaction with other cell types in the tumor environment [14].